A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

NCT ID: NCT02277691

Last Updated: 2017-08-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 341 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-07
• Study Completion Date: 2016-04-25

Brief Summary

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

Detailed Description

The drug being tested in this study is called TAK-536TCH. TAK-536TCH is being tested to treat people who have essential hypertension. The study looked at effectiveness and long-term safety of TAK-536TCH in people who took TAK-536CCB in addition to standard care.

The study enrolled 341 patients. Participants received:

• TAK-536CCB (as TAK-536/AML, 20 mg/5 mg) in run-in period,
• TAK-536TCH (as TAK-536/ AML/HCTZ, 20 mg/5 mg/12.5 mg) in treatment period
• TAK-536CCB and HCTZ 12.5 mg in treatment period

All participants were asked to take tablets at the same time each day throughout the study.

This multi-center trial was conducted in Japan. The overall time to participate in this study was 56 weeks (4 weeks run-in period and 52 weeks treatment period). Participants made multiple visits to the clinic during the study.

Conditions

Essential Hypertension

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAK-536TCH

For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.

For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast.

Group Type: EXPERIMENTAL

TAK-536TCH tablet

Intervention Type: DRUG

TAK-536TCH tablets

TAK-536CCB tablet

Intervention Type: DRUG

TAK-536CCB tablets

HCTZ 12.5 mg tablet

Intervention Type: DRUG

HCTZ tablets

Interventions

TAK-536TCH tablet

TAK-536TCH tablets

Intervention Type: DRUG

TAK-536CCB tablet

TAK-536CCB tablets

Intervention Type: DRUG

HCTZ 12.5 mg tablet

HCTZ tablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements.

2. The participant signs and dates a written informed consent form prior to the initiation of any study procedures.

3. The participant has essential hypertension.

4. The participant has an office sitting systolic blood pressure (SBP) of <180 mmHg and office sitting diastolic blood pressure (DBP) of < 110 mmHg at the start of the run-in period (Week -4). Participants receiving combined therapy with a 3-drug antihypertensive within 4 weeks prior to the start of the run-in period is required to have an office sitting SBP of < 160 mmHg and an office sitting DBP of < 100 mmHg.

5. The participant's office sitting blood pressure at Week -2 and at the end of the run-in period (Week 0) need to be either:

• Participants without concurrent diabetes mellitus or chronic kidney disease (CKD)*: Sitting SBP of ≥ 140 mmHg or sitting DBP of ≥ 90 mmHg
• Participants with concurrent diabetes mellitus or CKD*: Sitting SBP of ≥ 130 mmHg or sitting DBP of ≥ 80 mmHg.

• Estimate glomerular filtration rate according to creatinine (eGFRcreat) of <60 mL/min/1.73 m^2, or urinary albumin (spot urine) of ≥30 μg/mL in laboratory tests performed at Week -2 of the run-in period, and diagnosed with CKD by the investigator or subinvestigator.

6. The participant has an office sitting SBP of < 160 mmHg and office sitting DBP of < 100 mmHg at the end of the run-in period (Week 0).

7. The participant is male or female, aged 20 years or older at the time of providing informed consent.

8. The participant is an outpatient.

9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agree to use routinely adequate contraception from signing of informed consent through 1 month following the end of the study.

Exclusion Criteria

1. The participant has received any study drugs within 12 weeks prior to the start of the run-in period.

2. The participant has participated in another clinical study or a post-marketing study within 30 days prior to the start of the run-in period.

3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g. spouse, parent, child, sibling), or may consent under duress.

4. The participant requires taking prohibited concomitant drugs during the study.

5. The participant has a history of hypersensitivity or allergies to TAK-536, AML, HCTZ, any thiazide diuretic or analog, any dihydropyridine drug, or any analog of TAK-536TCH.

6. The participant is judged by the investigator or subinvestigator to be in danger of experiencing an excessive increase in blood pressure when changing or discontinuing premedication.

7. The participant received combination therapy with antihypertensive drugs of the 3 ingredients contained in TAK-536TCH.

8. The participant received combined therapy with antihypertensive drugs, including 4 or more components, within 4 weeks prior to the start of the run-in period.

9. The participant has secondary or malignant hypertension.

10. The participant has a difference of ≥ 20 mmHg between left and right arms in office sitting SBP at the start of the run-in period (Week -4).

11. The participant has apparent white coat hypertension or exhibits a white coat effect.

12. . The participant has a day-night reversed lifestyle, such as those working during the night.

13. The participant has sleep apnea syndrome requiring treatment.

14. The participant has any of the following cardiovascular diseases:

• Cardiac disease: Myocardial infarction*, coronary arterial revascularization*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia
• Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage*, transient ischemic attack*
• Vascular disease: Peripheral artery disease with intermittent claudication, artery dissection, aneurysm
• Advanced hypertensive retinopathy: With bleeding or exudate/papilledema** * Occurring or performed within 24 weeks of the start of the run-in period ** Observed within 24 weeks of the start of the run-in period

15. The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN).

16. The participant has a clinically severe renal disorder (e.g., eGFRcreat in laboratory tests performed at Week -2 of run-in period < 30 mL/minute/1.73 m^2).

17. The participant's body fluid sodium or potassium level is markedly low* or high*.

*Based on normal ranges

18. The participant has gout or a history of gout within 24 weeks of the start of the run-in period or has hyperuricemia requiring drug treatment.

19. The participant has uncontrolled diabetes (e.g., HbA1c ≥ 7.4% in laboratory tests performed at Week -2 of the run-in period).

20. The participant has a malignant tumor.

21. If female, the participant is pregnant or lactating or before giving informed consent, intending to become pregnant or donate ova during or within 1 month after participating in the study.

22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the run-in period.

23. The participant who, in the opinion of the investigator or subinvestigator, is unsuitable for any other reason.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Nagoya, Aichi-ken, Japan

Chiba, Chiba, Japan

Itojima-shi, Fukuoka, Japan

Kouriyama-shi, Fukushima, Japan

Sapporo, Hokkaido, Japan

Amagasaki-shi, Hyōgo, Japan

Tsukuba, Ibaragi, Japan

Morioka, Iwate, Japan

Sakaide-shi, Kagawa-ken, Japan

Takamatsu, Kagawa-ken, Japan

Kawasaki-shi, Kanagawa, Japan

Kyoto, Kyoto, Japan

Uji-shi, Kyoto, Japan

Sendai, Miyagi, Japan

Hirakata-shi, Osaka, Japan

Osaka, Osaka, Japan

Takatsuki-shi, Osaka, Japan

Saitama-shi, Saitama, Japan

Tokorozawa-shi, Saitama, Japan

Yaizu-shi, Shizuoka, Japan

Chiyoda-ku, Tokyo, Japan

Choufu-shi, Tokyo, Japan

Kodaira-shi, Tokyo, Japan

Koutou-ku, Tokyo, Japan

Setagaya-ku, Tokyo, Japan

Shinagawa-ku, Tokyo, Japan

Shinjuku-ku, Tokyo, Japan

Choufu-shi, , Japan

Kawasaki-shi, , Japan

Koutou-ku, , Japan

Morioka, , Japan

Sakaide-shi, , Japan

Setagaya-ku, , Japan

Shinagawa-ku, , Japan

Shinjuku-ku, , Japan

Tsukuba, , Japan

Uji-shi, , Japan

Yaizu-shi, , Japan

Countries

Japan

References

Rakugi H, Shimizu K, Nishiyama Y, Sano Y, Umeda Y. A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. Blood Press. 2018 Jun;27(3):125-133. doi: 10.1080/08037051.2017.1412797. Epub 2017 Dec 13.

Reference Type: DERIVED

PMID: 29235365 (View on PubMed)

Other Identifiers

U1111-1163-0169

Identifier Type: REGISTRY

Identifier Source: secondary_id

JapicCTI-142689

Identifier Type: REGISTRY

Identifier Source: secondary_id

TAK-536TCH/OCT-001

Identifier Type: -

Identifier Source: org_study_id